Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis.
BACKGROUND:Although clozapine is the gold-standard for treatment refractory schizophrenia, it has the worst metabolic profile of all antipsychotics. This is partly mediated by clozapine's impact on glucagon-like peptide (GLP-1). There is an absence of robust evidence for effective treatments fo...
Main Authors: | Dan J Siskind, Janni Leung, Anthony W Russell, Daniel Wysoczanski, Steve Kisely |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4909277?pdf=render |
Similar Items
-
Metformin reduces 12-month change in body weight among people newly commenced on clozapine: a retrospective naturalistic cohort study
by: Jessica Spokes, et al.
Published: (2021-03-01) -
Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review
by: Elias Wagner, et al.
Published: (2021-09-01) -
Prevalence and Predictors of Clozapine-Associated Constipation: A Systematic Review and Meta-Analysis
by: Ayala Shirazi, et al.
Published: (2016-06-01) -
Interaction of clozapine with metformin in a schizophrenia rat model
by: G. Horvath, et al.
Published: (2021-08-01) -
Clozapine associated pulmonary embolism: systematic review
by: Rakshya Poudyal, et al.
Published: (2019-07-01)